Excessive Sweating (Hyperhidrosis) Treatment Guide

Sweating is normal. What isn't normal is when it soaks through shirts at rest, makes handshakes a source of dread, or leaves visible drip marks after a five-minute presentation. That's hyperhidrosis — and for the patients I see with it, the condition often defines their daily life in ways that most people around them don't understand.

The numbers tell a stark story. Research published in Archives of Dermatological Research estimates that hyperhidrosis affects approximately 4.8% of Americans — roughly 15.3 million people.^[3] Among those affected, 70% report severe excessive sweating in at least one body area. Yet despite this, only about half have ever brought it up with a doctor, and just 27% receive a formal diagnosis.^[3] Some of the most common reasons patients give for not seeking care: they assumed nothing could be done, or they didn't realize it was a medical condition at all.

Both assumptions are wrong. Hyperhidrosis is a recognized, treatable medical disorder. This guide covers what I want every patient with excessive sweating to know — from how we tell primary from secondary disease, to exactly what each treatment option involves and who is a good candidate.

Primary vs. Secondary Hyperhidrosis: The First Distinction

Before any treatment discussion makes sense, you need to know which type of hyperhidrosis you have. The two types behave differently, have different causes, and require different approaches.

Primary Focal Hyperhidrosis

Primary hyperhidrosis has no identifiable underlying cause. It is believed to result from overactivity of hypothalamic thermoregulatory centers — the sweat glands themselves are normal, but they receive abnormally strong nerve signals. The condition is typically focal, meaning it affects specific areas rather than the whole body. Between 30 and 50% of patients have a family history of the condition, suggesting a genetic component.^[8]

The International Hyperhidrosis Society describes the diagnostic ABCs of primary hyperhidrosis:^[2]

• Age of onset: Usually childhood or adolescence
• Bilateral and symmetric: Both palms, both underarms — not one side
• Cessation during sleep: Primary hyperhidrosis does not cause night sweats
• Duration: Episodes occur at least twice weekly and have persisted for six months or more
• Emotional or thermal triggers: Worsens with stress, anxiety, heat, or exertion
• Family history: Present in up to 65% of cases

Secondary Generalized Hyperhidrosis

Secondary hyperhidrosis is caused by something else. It tends to affect the whole body rather than specific sites, can occur at night, and typically starts in adulthood rather than adolescence. When I see generalized sweating in a new patient — especially with night sweats — ruling out secondary causes comes first.

Medical conditions that can produce secondary hyperhidrosis include:

• Hyperthyroidism: One of the most common endocrine triggers; often accompanied by weight loss, palpitations, and heat intolerance
• Diabetes mellitus: Especially hypoglycemia-associated sweating and autonomic neuropathy
• Malignancy: Lymphoma (particularly Non-Hodgkin's lymphoma) and lung cancer are the most frequently identified cancers in secondary hyperhidrosis workups^[7]
• Pheochromocytoma and carcinoid tumors: Rare but must be excluded in appropriate clinical contexts
• Menopause and hormonal changes: Hot flashes involve a distinct thermoregulatory mechanism
• Infections: Tuberculosis was the most frequently identified infectious cause in one large secondary hyperhidrosis series^[7]
• Neurological conditions: Parkinson's disease, autonomic neuropathies, and spinal cord injuries

Medications are responsible for a meaningful share of secondary cases. Drug-induced hyperhidrosis is actually considered the most common form of secondary disease.^[9] Common offenders include SSRIs, tricyclic antidepressants, antipsychotics, opioids, systemic corticosteroids, thyroid medications, and certain diabetic drugs. If you started sweating more shortly after beginning a new medication, that timing is clinically important.

Making the Diagnosis: What Clinicians Assess

Primary focal hyperhidrosis is a clinical diagnosis. No laboratory test confirms it — the diagnosis rests on history, physical examination, and ruling out secondary causes. That said, validated tools exist to quantify severity and guide treatment decisions.

The Hyperhidrosis Disease Severity Scale (HDSS)

The HDSS is a single validated question used by dermatologists and primary care physicians worldwide. It rates severity on a 1–4 scale based on how much sweating interferes with daily activities:

A score of 3 or 4 defines severe hyperhidrosis. Clinically, a one-point HDSS improvement correlates with approximately a 50% reduction in sweat production, and a two-point improvement with about an 80% reduction.^[2] This makes it a practical outcome measure for tracking treatment response over time.

Quality-of-Life Impact: Why the Numbers Matter

In my experience, patients underestimate how much their sweating affects their quality of life — partly because they've normalized it over years. Research using the Dermatology Life Quality Index (DLQI) consistently shows that hyperhidrosis has a larger negative impact on quality of life than psoriasis, eczema, and severe acne.^[5] Pre-treatment DLQI scores in patients awaiting botulinum toxin have reached medians of 13.5 to 20, both indicating a "very large" to "extreme" effect on daily life.^[5]

The occupational and social consequences are real. Patients avoid handshakes, decline promotions requiring public speaking, choose clothing around sweat concealment, and limit physical intimacy. When I frame treatment for patients this way, they understand why addressing hyperhidrosis is not cosmetic — it is medical.

Body Site Patterns

The most common focal areas in primary hyperhidrosis are axillary (underarms), palmar (hands), plantar (feet), and craniofacial (head, face, scalp). Eighty-one percent of patients with primary hyperhidrosis report involvement of three or more sites simultaneously.^[10] This matters because some treatments are site-specific — iontophoresis works for hands and feet, Qbrexza is approved only for underarms, and botulinum toxin can be used in all four areas.

Stepwise Treatment: From First-Line to Last Resort

Treatment follows a clear progression. You start with the safest, least invasive options and escalate only when prior treatments have failed or are insufficient. Here is how the AAD and International Hyperhidrosis Society approach the treatment hierarchy.^[1]

Step 1 — Prescription Topical Antiperspirants (Aluminum Chloride 20%)

Prescription-strength aluminum chloride hexahydrate at concentrations of 20% (brands include Drysol, Hypercare, Xerac AC) is the standard first-line treatment for mild-to-moderate primary hyperhidrosis in all body sites. It works by mechanically plugging the eccrine sweat duct, temporarily blocking sweat output.

Application technique matters as much as the product itself. Apply to completely dry skin at bedtime — residual moisture causes irritation and reduces efficacy. Let it dry fully before contact with clothing or bed linens. Use nightly until excessive sweating is controlled (typically two to four weeks), then taper to once or twice weekly for maintenance. Over-the-counter antiperspirants are only effective for mild cases; most patients with clinically significant hyperhidrosis need prescription-strength concentrations.

The main side effect is skin irritation. Applying to fully dry skin, using a gel formulation, and spacing applications can reduce this. There is no credible evidence linking aluminum chloride to Alzheimer's disease or breast cancer — the Alzheimer's Association and American Cancer Society have both addressed these concerns directly.^[1]

Step 2 — Qbrexza (Glycopyrronium Tosylate Cloth 2.4%)

Qbrexza represents a meaningful advance in topical hyperhidrosis treatment. It is the only FDA-approved topical anticholinergic specifically indicated for primary axillary hyperhidrosis in patients aged 9 and older, approved in June 2018.^[6] Unlike aluminum chloride, which physically blocks sweat ducts, Qbrexza works pharmacologically — the glycopyrronium molecule blocks muscarinic acetylcholine receptors on sweat glands, reducing their secretory activity.

Each pre-moistened cloth is used once daily to wipe both underarms before bedtime. Apply to dry skin; if you've recently showered, wait 30 minutes. Wash hands immediately after application and keep the cloth away from eyes and face, where it can cause temporary blurring and irritation. Dispose of the cloth right away — glycopyrronium can cause anticholinergic effects in children or pets who contact it.

In the phase 3 clinical trials (n=244 per arm), Qbrexza produced significant improvements in HDSS scores, gravimetrically measured sweat production, and quality-of-life measures compared to placebo.^[6] Long-term open-label extension data at 44 weeks confirmed durable efficacy with no new safety signals. Side effects are primarily anticholinergic: dry mouth (most common), dilated pupils and light sensitivity, sore throat, and mild underarm skin irritation.

Step 3 — Iontophoresis (Hands and Feet)

Iontophoresis is the first-line procedure for palmar and plantar hyperhidrosis — the two areas where topical treatments are often least practical. The device passes a mild direct electric current through shallow trays of tap water in which the patient submerses hands or feet. The current is believed to temporarily disrupt sweat gland function, though the precise mechanism remains incompletely understood.

Initial treatment requires 20 to 30 minutes per session, performed daily or every two to five days. Most patients reach meaningful improvement after five to ten sessions, then transition to weekly or biweekly maintenance. Adding anticholinergic medication to the water can improve efficacy for treatment-resistant cases. FDA-cleared devices are available for home use; the upfront cost is offset by the elimination of office visits for ongoing maintenance. Side effects are minor — occasional burning or tingling; mild burns can occur if the device is misused.

Step 4 — Oral Anticholinergic Medications

Oral agents become appropriate when topical and procedural treatments have provided incomplete relief, when sweating involves multiple body sites simultaneously, or when a patient has areas — like the groin, lower back, or beneath the breasts — that are difficult to treat locally.

Glycopyrrolate (Robinul) is the most commonly prescribed oral agent for hyperhidrosis. It does not cross the blood-brain barrier as readily as other anticholinergics, which reduces central nervous system side effects like confusion and sedation. Dosing typically starts at 1 mg two to three times daily, taken on an empty stomach for better absorption, and is titrated up to a maximum of 8 mg per day based on response and tolerability. One clinical study found that approximately 80% of patients responded to treatment, though roughly one-third discontinued due to side effects.^[11] Glycopyrrolate is not FDA-approved for hyperhidrosis specifically — it is used off-label, though it is well-supported by the literature and recommended by the International Hyperhidrosis Society.^[2]

Oxybutynin (Ditropan) is the other frequently used oral anticholinergic. It is primarily indicated for overactive bladder but is prescribed off-label for hyperhidrosis. One study of 50 patients found that 70% reported improvements in palmar and axillary sweating, with 90% reporting plantar improvement as well. Side effects including moderate-to-severe dry mouth, constipation, blurred vision, and drowsiness were reported in 35% of patients at the six-week mark.^[11] Oxybutynin is generally started at 2.5 mg once daily and adjusted upward based on tolerability.

Both medications impair your ability to sweat throughout the body, which means avoiding hot environments becomes important. Patients should be counseled about the risk of heat exhaustion during outdoor activity or high-temperature exposure while on these medications.

Step 5 — Botulinum Toxin Injections

Botulinum toxin (Botox) injections are FDA-approved for the treatment of primary axillary hyperhidrosis and are widely used off-label for palmar, plantar, and craniofacial sweating. The mechanism is direct: botulinum toxin blocks the release of acetylcholine at the neuromuscular junction of eccrine sweat glands, temporarily halting their secretory activity in the injected area.

Most patients notice a meaningful reduction in sweating within 7 to 10 days. Duration of results varies by body site — underarm and hand injections typically last 3 to 10 months; foot injections last approximately 3 to 6 months; and facial treatments around 4.5 months.^[1] Patients require repeat treatments to maintain results, which is a real consideration for long-term planning and cost.

Before your injections, stop aspirin and anti-inflammatory medications — along with vitamin E — to reduce the risk of bruising and bleeding at the injection sites. Side effects include injection-site pain, bruising, headache, and temporary muscle soreness. For palmar injections specifically, mild transient weakness of intrinsic hand muscles can occur. Receiving treatment from a board-certified dermatologist significantly reduces the risk of complications from improperly placed injections.

Axillary vs. Palmar vs. Plantar vs. Craniofacial

Not all body sites respond equally to the same treatments. Matching intervention to anatomy is central to an effective treatment plan.

Palmar hyperhidrosis carries particularly high functional impact — activities requiring fine motor control, keyboard use, and instrument playing are directly impaired. Iontophoresis is the most practical long-term solution for many patients with hand sweating, given that botulinum toxin requires repeat injections and carries a small risk of temporary intrinsic hand muscle weakness.

Craniofacial hyperhidrosis deserves special mention because it is visually obvious in social settings and emotionally distressing. Oral glycopyrrolate is often the first medication I reach for in craniofacial cases because topical application to the face is less practical, and the systemic anticholinergic effect addresses facial sweating directly.

Endoscopic Thoracic Sympathectomy: The Last Option

Endoscopic thoracic sympathectomy (ETS) is a minimally invasive surgical procedure that interrupts the thoracic sympathetic chain — the nerve pathway responsible for triggering sweating in the upper body. It is performed under general anesthesia through small incisions, typically as an outpatient procedure. The target ganglia are usually T2–T3 for palmar hyperhidrosis and T2–T4 for axillary or combined disease.

The results are dramatic. ETS achieves success rates above 95% for palmar hyperhidrosis, with immediate postoperative anhidrosis (dryness) in the treated areas. A 20-year follow-up study of patients who underwent bilateral ETS found that palmar and axillary anhidrosis was maintained in the vast majority of patients, with high overall satisfaction scores that remained consistent from the 1-year to the 20-year assessment.^[12]

The unavoidable trade-off is compensatory sweating — increased perspiration in areas below the level of sympathectomy, most commonly the abdomen, back, and legs. Virtually all patients experience some degree of this; in most cases it is mild to moderate and considered preferable to the original problem. A European Journal of Cardio-Thoracic Surgery study found that 34.7% of ETS patients reported compensatory sweating, with the majority classified as mild.^[13] Anxiety levels, which are commonly elevated before surgery, decreased significantly and remained low at long-term follow-up despite the presence of compensatory sweating.

The key message I give patients considering ETS is this: it is highly effective, but it trades one set of sweating symptoms for another. Compensatory sweating cannot be reliably predicted in severity. Detailed informed consent and realistic expectations are non-negotiable before proceeding.

Ruling Out Secondary Causes: What the Workup Looks Like

When a patient presents with generalized sweating, night sweats, new-onset hyperhidrosis in adulthood, or sweating associated with other symptoms like weight loss, palpitations, or fatigue, secondary causes must be ruled out before any primary hyperhidrosis treatment begins.

The workup I typically order is guided by the clinical picture:

• Thyroid function tests (TSH, free T4): Hyperthyroidism is common and often presents with sweating alongside other symptoms
• Fasting glucose and HbA1c: To screen for diabetes and hypoglycemia-related sweating
• Complete blood count: Lymphoma can present with night sweats; abnormal CBC or lymphadenopathy warrants further workup
• 24-hour urine catecholamines or plasma metanephrines: If pheochromocytoma is suspected based on episodic hypertension, headache, or palpitations
• Chest X-ray: To evaluate for tuberculosis or mediastinal lymphadenopathy
• Full medication review: Often the most actionable part of the workup — identifying and changing a causative medication can resolve secondary hyperhidrosis without further treatment

Primary hyperhidrosis, once confirmed, is diagnosed by the clinical picture alone. There is no blood test that confirms it — diagnosis is based on meeting the established criteria: focal sweating at characteristic sites, bilateral symmetry, onset before age 25, cessation during sleep, frequency of at least twice weekly, duration over six months, and a positive family history in most cases.^[8]

Telehealth's Role: What Can Be Done Remotely

Hyperhidrosis is one of the conditions where telehealth adds genuine value. Most of the diagnostic work — establishing primary vs. secondary type, assessing HDSS severity, reviewing medication history, and ordering appropriate labs — can be done through a thorough video visit. And the most effective early-stage treatments are prescribable without a physical exam.

A telehealth physician can prescribe prescription-strength aluminum chloride 20%, Qbrexza (glycopyrronium cloth) for axillary hyperhidrosis, and oral anticholinergics including glycopyrrolate and oxybutynin when clinically appropriate for patients with primary focal hyperhidrosis and no red flags for secondary disease. Glycopyrrolate is not a controlled substance, which means it can be prescribed through standard telehealth workflows across most states.

The AAFP and International Hyperhidrosis Society guidelines emphasize a stepwise approach starting with topical agents and escalating to oral medications, with specialist referral for procedural treatments when needed. Telehealth fits cleanly into the first two tiers of that hierarchy.

What telehealth cannot do: botulinum toxin injections, iontophoresis supervision, miraDry, or ETS evaluation all require in-person care. Patients with signs of secondary hyperhidrosis — generalized sweating, night sweats, weight loss, new-onset disease in adulthood — warrant an in-person evaluation to complete the appropriate workup. For those patients, a telehealth visit can still serve as an efficient entry point that speeds the referral process.

TeleDirectMD physicians are reachable by phone at 678-956-1855 or by email at contact@teledirectmd.com.

When to Seek Prompt Medical Attention

Sweating that occurs only at night, or only on one side of the body, is not consistent with primary hyperhidrosis. These presentations warrant a clinical evaluation before any symptomatic treatment is started.

Frequently Asked Questions